Tylenol Autism Lawsuit Update: Second Circuit Denies Rehearing, Clearing 500+ Cases for Remand

The latest Tylenol autism lawsuit update is a defeat for Kenvue: on Friday, October 16, 2026, the U.S. Court of Appeals for the Second Circuit denied the company's petition for panel rehearing and rehearing en banc, leaving in place its July 13 decision that revived about 500 federal lawsuits alleging that prenatal acetaminophen use caused autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD). The cases now head back to U.S. District Judge Denise Cote in Manhattan unless Kenvue persuades the appeals court or the Supreme Court to hold the mandate while it seeks certiorari, which it has said it will do.

The order is short and, by every account of it, gives no reasons. Its effect is not short. It ends the defense's best chance to undo, inside the Second Circuit, the most prominent appellate reading of amended Federal Rule of Evidence 702 that has gone against a pharmaceutical defendant. It also starts two clocks that every lawyer with an acetaminophen inventory now needs on the calendar: the seven-day mandate period under the Federal Rules of Appellate Procedure, and the 90-day window to petition the Supreme Court.

Tylenol autism lawsuit update: what the Second Circuit did on October 16

The petition had been pending since Thursday, September 10, 2026, when Kenvue Brands LLC, joined by retail co-defendants Walgreen Co., Costco Wholesale Corp. and CVS Health Corp., asked the July panel to reconsider and, failing that, asked the full court to rehear the appeal. The court allowed amicus filings in support of rehearing by an order dated September 29, and five arrived, from PhRMA, the U.S. Chamber of Commerce with the American Tort Reform Association, the National Association of Manufacturers, Lawyers for Civil Justice and the Atlantic Legal Foundation. That coalition argued that the panel had effectively read the 2023 amendment to Rule 702 out of the rulebook.

None of it moved the court. Reuters, Law360, AboutLawsuits and LegalScoops all reported that the October 16 order denies both forms of relief. The panel declined to revisit its own reasoning, and no active judge secured a majority for en banc review. Public reports do not describe any dissent from the denial or any statement respecting it, and no vote tally has been reported. For a court that rehears so few appeals en banc, the outcome was the expected one; the amicus order had been the only modest sign that the petition was being taken seriously.

Kenvue's response came the same day. A company spokesperson said it would ask the U.S. Supreme Court to review the decision, arguing that the Second Circuit had disregarded the safeguards the federal judiciary has built for evaluating expert testimony, and reiterated the company's position that acetaminophen is safe when used as directed.

Did the Second Circuit deny rehearing in the Tylenol autism case?

Yes. On October 16, 2026, the Second Circuit denied both panel rehearing and rehearing en banc in Rutledge v. Walgreen Co. and the consolidated appeals from Multidistrict Litigation (MDL) No. 3043. The July 13 opinion therefore stands as the law of the circuit, and the revived cases will return to the Southern District of New York once the mandate issues.

Two features of the denial matter for what comes next.

First, a denial of rehearing is not a new merits decision. It adds nothing to the July opinion and subtracts nothing from it. Lawyers on both sides will be litigating the remand from the text of the July 13 opinion, and the Supreme Court, if it is asked, will be reviewing that same opinion.

Second, the denial triggers the procedural deadlines. Under Federal Rule of Appellate Procedure 41(b), a court of appeals issues its mandate seven days after the time to petition for rehearing expires or seven days after the court denies a timely petition, whichever is later. Seven days from Friday, October 16 is Friday, October 23, 2026. Under Supreme Court Rule 13.3, the 90-day period to petition for certiorari runs from the date rehearing was denied, not from the July judgment, so the deadline is Thursday, January 14, 2027.

Why the en banc denial surprised almost no one

The Second Circuit is the federal appeals court least inclined to rehear cases en banc. Practitioner studies by Perkins Coie and Morrison Foerster have documented how rarely the full court convenes; the circuit's long-standing practice is to leave panel decisions in place even when individual judges disagree with them, and to express disagreement, if at all, through statements accompanying a denial. Against that background, a petition that asked the full court to second-guess how a panel applied an abuse-of-discretion standard to a scientific record faced long odds from the day it was filed.

That context also explains why the defense invested so heavily in amicus support. The goal was less to win en banc review than to build a record of institutional concern, from the pharmaceutical industry, manufacturers, the business community and the defense bar, that a later certiorari petition could point to. The Tylenol autism lawsuit update for defense counsel, then, is that the October 16 denial was step one of a two-step plan, and the second step runs through Washington.

For plaintiffs, the same history cuts the other way. The absence of any reported dissent from the denial means a certiorari petition cannot point to judges within the circuit who thought the panel erred badly enough to warrant full-court review. Petitions that arrive with an en banc dissent attached tend to attract more attention at the Supreme Court than those that do not.

What the July 13 decision held

The underlying opinion, written by Judge Guido Calabresi and joined by Judges Gerard Lynch and Eunice Lee, resolved consolidated appeals captioned Rutledge v. Walgreen Co. and Phippen v. Walgreen Co. (No. 24-916 as the lead docket, with Nos. 24-1121, 24-2360 and 24-2594). It reviewed Judge Cote's December 18, 2023 order excluding all five of the plaintiffs' General Causation experts, the summary judgment that followed, and the later dismissal of the remaining MDL cases.

The standard of review favored the defense on paper. A district court's decision to admit or exclude expert testimony is reviewed for abuse of discretion and will not be disturbed unless it is "manifestly erroneous." The panel nonetheless held that Judge Cote "exceeded" her discretion as to three experts, because she had substituted her own weighing of contested epidemiology for the question Rule 702 actually asks: whether each expert reliably applied a method accepted in the expert's field.

The panel's treatment of "cherry-picking," the defense's central charge, is the passage most likely to be cited in other MDLs. The court reasoned that it is not cherry-picking "for an expert to prefer one study to another" where the expert offers a coherent, scientifically plausible reason for the preference. Disagreement about which studies deserve more weight, on that view, is material for cross-examination and competing experts rather than a ground for exclusion.

The expert scorecard

Expert	Discipline in the MDL	District court (Dec. 2023)	Second Circuit (July 2026)	Status after Oct. 16 denial
Dr. Andrea Baccarelli	Epidemiology	Excluded	Exclusion reversed	May testify on remand, subject to any renewed challenge on grounds the panel left open
Dr. Eric Hollander	Psychiatry	Excluded	Exclusion reversed	Same
Dr. Brandon Pearson	Toxicology and environmental health	Excluded	Exclusion reversed	Same
Dr. Robert Cabrera	Teratology and genetics	Excluded	Exclusion affirmed	Remains excluded
Dr. Stan Louie	Pharmacology	Excluded	Exclusion affirmed	Remains excluded

The split result matters. The plaintiffs did not win a blanket ruling that Rule 702 challenges go to weight. They won a ruling that, on this record, three specific experts used methods that other scientists in their fields use, and that the district court went too far in rejecting them. Two experts' exclusions stand. That mixed outcome is one reason the defense will find it harder to frame the case for the Supreme Court as a clean doctrinal split.

Did the court rule on preemption?

Yes, against the defendants. The manufacturers and retailers argued that federal labeling law for over-the-counter drugs preempts state-law Failure to Warn claims. The panel agreed with the district court that Preemption (Products) does not bar the claims. Acetaminophen sold over the counter must carry the general pregnancy and breast-feeding warning required by 21 C.F.R. § 201.63 for drugs intended for systemic absorption, but, as the opinion observed, the governing monograph does not expressly prohibit additional warnings not specified in it. The court also noted that the FDA does not require any ADHD- or ASD-specific warning on acetaminophen and that the defendants do not give one.

The court was careful about scope. It said it was not deciding whether acetaminophen causes ADHD or ASD, and not deciding whether manufacturers must warn about any alleged risk. Those questions remain for remand and, eventually, for juries.

How many Tylenol autism lawsuits were revived?

About 500. Reuters and CNBC reported in July, and Reuters repeated on October 16, that the decision revives more than 500 private lawsuits; some plaintiff-side trackers put the figure closer to 550. The difference reflects how counters treat later-filed cases, plaintiffs who were dismissed in the August 2024 sweep, and cases pending in state courts that the federal ruling does not directly govern.

Kenvue's own public filings describe the federal procedural history rather than a current count. Its quarterly report for the period ended June 28, 2026 states that the federal cases were centralized in the Southern District of New York in October 2022, that final judgment for the defendants was entered in February 2024, that the remaining MDL cases were dismissed in August 2024, and that in July 2026 the Second Circuit vacated the judgment, affirming in part and reversing in part and remanding for further proceedings. The same filings note that suits have also been filed in state courts against Johnson & Johnson Consumer Inc., Kenvue and Johnson & Johnson.

For anyone tracking the Tylenol autism lawsuit update by update, a firm census will likely come from Judge Cote once the docket reopens. Transferee judges routinely require plaintiffs to confirm whether they intend to proceed after an appellate reversal, and the figure that emerges from that exercise, rather than any press estimate, will become the working number for case management and any later settlement discussion.

Will Kenvue appeal the Tylenol ruling to the Supreme Court?

Kenvue says it will. The company announced after the October 16 denial that it plans to petition the U.S. Supreme Court, and it has until January 14, 2027 to do so, or until as late as March 15, 2027 if a Justice grants the maximum 60-day extension available under Supreme Court Rule 13.5.

Whether the Court would take the case is a different question, and the most recent signal is not encouraging for the defense. On May 26, 2026, the Supreme Court denied certiorari in Union Carbide Corp. v. Sommerville, No. 25-919. That petition, arising from a West Virginia ethylene oxide medical-monitoring class action, asked the Court to decide whether challenges to the factual basis of an expert's opinion always go to weight rather than admissibility, a question the Fourth Circuit had answered in the plaintiffs' favor at 149 F.4th 408 (4th Cir. 2025). The Washington Legal Foundation, the Atlantic Legal Foundation and Hollingsworth LLP filed amicus briefs urging review. The Court declined anyway.

A Kenvue petition would differ from Sommerville in ways that could help or hurt:

• Stakes and salience. The acetaminophen litigation touches a drug taken by a large share of pregnant patients and a question that federal health officials have publicly engaged since September 2025. That visibility can attract the Court's attention, but the Court does not grant review because a case is prominent; it grants review to resolve conflicts on recurring legal questions.
• The posture is interlocutory in substance. The Second Circuit did not enter judgment for the plaintiffs. It sent the cases back for further proceedings, and the defense can renew Rule 702 challenges on grounds the panel did not foreclose and can contest specific causation case by case. The Supreme Court is often reluctant to intervene before a case is final in that practical sense.
• The mixed result. Because the panel affirmed two exclusions and reversed three, the opinion reads as record-specific application of an agreed standard. Petitioners typically need to show a clean conflict in the governing rule; a dispute about how a correct rule was applied to five experts is weaker material.
• A preemption question rides along. A petition could pair the Rule 702 issue with the OTC-monograph preemption holding. Preemption questions involving FDA regulation have drawn the Court's interest in the past, and a petition that presents both could look more substantial than Sommerville did.

Key dates after the rehearing denial

Step	Rule	Date
Rehearing (panel and en banc) denied	FRAP 40	Friday, October 16, 2026
Mandate due absent a stay	FRAP 41(b): seven days after denial	Friday, October 23, 2026
Stay of mandate pending certiorari, if sought and granted	FRAP 41(d): ordinarily up to 90 days, continuing if a petition is filed and until the Court rules	Must be moved for before the mandate issues
Certiorari petition due	Sup. Ct. R. 13.3: 90 days from denial of rehearing	Thursday, January 14, 2027
Latest possible petition with extension	Sup. Ct. R. 13.5: up to 60 additional days	Monday, March 15, 2027

What happens next in the Tylenol autism MDL?

The immediate question is whether the mandate issues on October 23 or is stayed. FRAP 41(d) allows a party to move to stay the mandate pending a certiorari petition; the motion must show that the petition would present a substantial question and that there is good cause for a stay. If the Second Circuit grants a stay, the cases stay in appellate limbo for up to 90 days, and longer if Kenvue files its petition within that time, until the Supreme Court acts. If the court denies a stay, the mandate issues and jurisdiction returns to Judge Cote while any petition is pending.

Once the cases are back in the Southern District of New York, the practical sequence is likely to look like this:

1. Reopening the docket. The district court will need to vacate the judgments as directed, restore the dismissed cases, and decide how to treat cases dismissed in August 2024 that were tied to the earlier rulings.
2. A new case management order. Expect directions on plaintiff confirmations, updated Plaintiff Fact Sheet (PFS) submissions, and a census of who is still pursuing claims. The court may also set terms for new filings and for cases transferred in after the mandate.
3. Renewed expert motions. The panel's ruling binds the district court on the three reinstated experts as to the grounds it addressed, but it does not immunize every later opinion those experts offer. Defendants can be expected to challenge supplemental reports, new studies and case-specific opinions under the same rule.
4. Specific causation. The July opinion dealt with General Causation, whether acetaminophen can cause ASD or ADHD at all. Each plaintiff must still prove Specific Causation: that prenatal exposure caused that child's condition. That is where most of the remaining scientific fight will happen.
5. Bellwether selection. If the docket proceeds, the court will need a pool of representative cases for any Bellwether Trial program. Nothing in the public record yet indicates a trial date.

None of that will move quickly. Judge Cote dismissed the cases nearly two years before the appellate ruling, and the parties will need time to rebuild discovery and expert schedules. A first federal trial in 2027 would be fast by mass-tort standards.

Has any court ruled that Tylenol causes autism?

No. No court has found that prenatal acetaminophen use causes autism or ADHD. The Second Circuit said expressly that it was not deciding whether a general causal relationship exists, and the October 16 denial adds no finding of any kind. What the appellate ruling decided is narrower: that three of the plaintiffs' experts may present their opinions, and that a jury, rather than the judge acting as gatekeeper, should weigh the competing science if the cases reach trial.

The scientific picture remains contested. In September 2025, the FDA initiated a label change and sent a letter to physicians saying that acetaminophen use in pregnancy may be associated with an increased risk of neurological conditions such as autism and ADHD, while also stating that a causal relationship had not been established and that the studies were contradictory. Medical organizations including the American College of Obstetricians and Gynecologists criticized that move. Kenvue has consistently maintained that acetaminophen does not cause autism and that the science supports its safety in pregnancy.

Is there a Tylenol autism settlement?

No. There is no settlement, settlement program or Global Settlement framework in the acetaminophen litigation, and neither side has publicly signaled negotiations. Settlement values quoted on lawyer-advertising pages are speculation.

The rehearing denial does change the settlement calculus at the margin. Before October 16, the defense could tell investors and opposing counsel that a full-court rehearing or a stay might restore the dismissal. That path is now closed in the Second Circuit. What remains is the Supreme Court route, renewed expert challenges on remand, and Specific Causation fights, each of which carries real but uncertain value for the defense. Plaintiffs' firms, for their part, know that the three reinstated experts face continued scrutiny and that two of their original five experts remain excluded.

Regulators, Texas and the Kimberly-Clark deal

Three developments outside the MDL shape how the federal cases will be litigated.

The FDA label action. The September 22, 2025 initiative to update acetaminophen labeling has not, on the public record reviewed for this article, produced a finalized ASD- or ADHD-specific warning. That matters for the preemption analysis: the Second Circuit's holding rests partly on the absence of any FDA-required neurodevelopmental warning and on the monograph's silence about additional warnings. A future FDA-mandated warning would not retroactively cure past labeling, but it would shape both sides' arguments about what a reasonable manufacturer should have said and when.

The Texas attorney general's suit. Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue on October 28, 2025, alleging that the companies violated Texas consumer protection law by concealing risks of prenatal acetaminophen use, and that Johnson & Johnson fraudulently transferred Tylenol liabilities to Kenvue. A trial court refused to dismiss the case. At oral argument on June 25, 2026 in the state's statewide appellate court, Chief Justice Scott Brister signaled skepticism that Kenvue Inc. and Johnson & Johnson are proper defendants because they do not themselves market or sell Tylenol in Texas. No decision on that appeal surfaced in the reporting reviewed for this article. The state case runs on its own track, but the Second Circuit's preemption holding, though not binding on Texas courts, will be cited there.

The Kimberly-Clark acquisition. Kimberly-Clark agreed on November 3, 2025 to acquire Kenvue in a cash-and-stock transaction valued at about $48.7 billion. Shareholders of both companies approved the deal on January 29, 2026, the U.S. antitrust waiting period expired on February 4, 2026, and Kimberly-Clark's quarterly report for the period ended June 30, 2026 said it expected the deal to close in the second half of 2026, subject to remaining conditions including foreign regulatory approvals. The European Commission's clearance, conditioned on divestiture of certain feminine-care products, was reported in mid-October. Once the transaction closes, decisions about a certiorari petition, a mandate stay and any eventual resolution will sit with a combined company that priced Tylenol litigation risk into its offer.

Tylenol autism lawsuit update timeline: from MDL to rehearing denial

Date	Event
October 2022	Judicial Panel on Multidistrict Litigation (JPML) centralizes federal acetaminophen ASD-ADHD cases as MDL No. 3043 before Judge Denise Cote, S.D.N.Y.
December 1, 2023	Amended Federal Rule of Evidence 702 takes effect
December 18, 2023	Judge Cote excludes all five of plaintiffs' general causation experts
February 2024	Final judgment entered for defendants in the initial cases
August 2024	Remaining MDL cases dismissed
September 22, 2025	FDA initiates acetaminophen label change and physician letter on pregnancy use
October 28, 2025	Texas attorney general sues Johnson & Johnson and Kenvue
November 3, 2025	Kimberly-Clark agrees to acquire Kenvue for about $48.7 billion
May 26, 2026	Supreme Court denies certiorari in Union Carbide Corp. v. Sommerville, No. 25-919 (Rule 702)
June 25, 2026	Texas appellate argument on whether Kenvue and J&J are proper defendants
July 13, 2026	Second Circuit reinstates three experts, affirms two exclusions, rejects preemption, revives about 500 cases
September 10, 2026	Kenvue, Walgreen, Costco and CVS petition for panel or en banc rehearing
September 29, 2026	Second Circuit order allows amicus briefs supporting rehearing
October 16, 2026	Second Circuit denies panel rehearing and rehearing en banc
October 23, 2026	Mandate due under FRAP 41(b) absent a stay
January 14, 2027	Certiorari petition deadline (extendable to March 15, 2027)

What it means for practitioners

The practical Tylenol autism lawsuit update for every audience is that the denial converts a contested appellate ruling into settled Second Circuit law, at least until the Supreme Court says otherwise. Each audience that follows mass torts should read it differently.

For MDL defense counsel

The Rutledge opinion is now a precedent that plaintiffs will cite in every Daubert Challenge where the expert's methodology is mainstream but the judge reads the literature differently. Defense briefs in the Second Circuit, and in transferee courts elsewhere that look to it, will need to frame Rule 702 objections around flawed application of method, unsupported analytical leaps, and fit to the facts rather than disagreement with an expert's weighting of studies. The two affirmed exclusions are the template: the panel was willing to uphold exclusion where the expert's reasoning, not the weight of evidence, failed. The Sommerville denial is also a reminder that the Supreme Court has so far declined to referee how circuits apply the 2023 amendment.

For plaintiffs' firms

The ruling reopens an inventory that many firms wrote off in 2024. Before relying on it, firms should audit what happened to each client's case: whether it was dismissed with the MDL, whether any appeal or tolling preserved it, and whether the Statute of Limitations or a Statute of Repose has run under the governing state law for clients who never filed. New intake will face the same questions, and the Discovery Rule will be argued hard in both directions given how publicly the alleged link has been debated since 2022. Firms should also expect the court to scrutinize specific causation evidence early, possibly through a Lone Pine Order or similar screening mechanism, given the size of the docket and the history of the litigation.

For retailers and store-brand sellers

Walgreen, Costco and CVS were petitioners because store-brand acetaminophen is a large part of the alleged exposure. The preemption holding, that the monograph does not forbid additional warnings, applies to them as well as to Kenvue. Retailers that sell private-label OTC products should expect their indemnity and supply-agreement terms with manufacturers to matter more than they did when the cases were dismissed.

For transferee judges in other MDLs

Judges handling dockets where General Causation turns on contested epidemiology, including GLP-1 drugs, hair relaxers and the baby food heavy-metals litigation, now have a binding example of a circuit reversing an exclusion under amended Rule 702. The opinion does not tell them to admit every expert; it tells them to keep the gatekeeping inquiry focused on reliability of method and application, and to leave disputes over the relative weight of studies to the jury.

For litigation funders and the broader plaintiffs' bar

A revived docket of roughly 500 cases, with the possibility of new filings, is a capital event. Third-Party Litigation Funding providers that financed acetaminophen inventories before 2024 will be revaluing positions. Anyone extending new capital should price the cert petition, the remand schedule and specific-causation risk, and should expect transferee judges, as other MDL judges have done this year, to ask questions about who is financing large inventories.

Frequently asked questions

What happened in the Tylenol autism lawsuit this week?

On October 16, 2026, the Second Circuit denied Kenvue's petition for panel rehearing and rehearing en banc, leaving intact its July 13 ruling that revived about 500 federal lawsuits claiming prenatal acetaminophen use caused autism or ADHD. Kenvue says it will seek Supreme Court review.

When will the Tylenol cases go back to Judge Cote?

The mandate is due on October 23, 2026 under Federal Rule of Appellate Procedure 41(b). If Kenvue moves to stay the mandate pending a certiorari petition and the court grants the motion, the return to the district court will be delayed until the Supreme Court acts on the petition.

How many Tylenol autism lawsuits are there?

About 500 federal cases were revived by the July 13, 2026 ruling, according to Reuters and other outlets; some trackers report about 550. Additional cases are pending in state courts, and the federal number may change once the district court takes a census on remand.

Did the court say Tylenol causes autism?

No. The Second Circuit expressly declined to decide whether acetaminophen causes autism or ADHD. It held only that three plaintiffs' experts were wrongly excluded and that federal labeling law does not preempt the failure-to-warn claims.

Is there a Tylenol autism settlement?

No. There is no settlement or settlement program, and no public sign of negotiations. Any settlement figures circulating online are speculative.

Can I still file a Tylenol autism lawsuit?

Claims remain possible, but eligibility turns on state-law filing deadlines, the facts of exposure and diagnosis, and how the district court manages the remanded docket. Whether a particular claim is timely depends on the governing statute of limitations and discovery rule, which is a question for a licensed attorney in the relevant state.